Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Dexcom G6 is now covered by RAMQ, BC PharmaCare, and Saskatchewan Health

The Dexcom G6 CGM System is now covered in Québec by RAMQ, in British Columbia by BC PharmaCare, and in Saskatchewan by Saskatchewan Health. Conditions apply. Click the links below for more information.

Quebec (RAMQ)

British Columbia (BC PharmaCare)

Saskatchewan (Saskatchewan Health)

Helping improve glycemic control

Proven Outcomes

A growing amount of evidence substantiates the efficacy of Dexcom Continuous Glucose Monitoring (CGM) Systems for insulin-using patients with Type 1 or Type 2 diabetes.

Reduction in A1C

Use of Dexcom CGM has demonstrated significant A1C reductions regardless of education level, math ability, and age.1
  • The DIAMOND Study shows an average of 1.3% A1C reduction in patients with baseline A1C > 8.5%.1
Click to expand
Significant A1C reductions demonstrated regardless of education level, math ability, and age1
Click to expand
HypoDE study showed significant reduction in hypo events in high-risk patients with T1D treated with MDI

Reduction of Hypoglycemia

Several studies have shown that use of Dexcom CGM reduces hypoglycemia.
  • 65% reduction in hypoglycemic events when switching from FGM to CGM.4
  • Average 72% reduction in number of hypoglycemic events when using CGM.†,6

Increased Time in Range

Use of Dexcom CGM has been shown to increase time in range (TIR).*,1,3,4,5
  • Increase of +1hr 47min in median time in range per day in patients who switched from FGM to CGM.4
Click to expand
Click to expand
Patients demonstrated significant A1C reductions (avg of 1%), regardless of education level, diabetes numeracy, and age

High rate of adherence

After 24 weeks of use, 93% of study participants were still using the Dexcom CGM System ≥ 6 days/week.1
Keep up with the latest news and information.

Stay up-to-date
with Dexcom

Sign up to stay up-to-date with the latest CGM news, product updates and educational events.

† Participants randomized to CGM in COMISAIR used a mix of CGM devices—those in the CGM+Pump group used Dexcom G4 or Medtronic sensors while those in the CGM+MDI group used Dexcom G4; those in GOLD used Dexcom G4 (without Software 505); those in DIAMOND and HypoDE used Dexcom G4 with Software 505, the same algorithm used in Dexcom G5® Mobile.
‡ Hypoglycemic event defined as glucose values ≤3.0 mmol/L sustained for at least 20 minutes, preceded by a minimum of 30 minutes with glucose values >3.0 mmol/L.
* Time in range defined as 3.9-10.0 mmol/L)/per day
1 Beck RW, et al. JAMA 2017;317:371-78.
2 Lind M, et al. JAMA 2017;317:379-87.
3 Šoupal J, et al. Diabetes Care 2020;43:37–43.
4 Reddy M, et al. Diabetes Technol Ther 2018;20:751–57.
5 Reddy M, et al. Diabet Med 2018;35:483–90.
6 Heinemann L, et al. Lancet 2018;391:1367-1377